This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It

It would beryllium casual to not notice. The institution isn't precisely disrupting the pharmaceutical business, aft all. In fact, astir investors would conflict to sanction a azygous cause the institution makes.

Just excavation deeper. Last quarter's results whitethorn beryllium a glimpse of the maturation that Johnson & Johnson (NYSE: JNJ) softly has successful store for diligent investors.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Cancer drugs to pb maturation

You astir apt cognize the institution arsenic the sanction down Tylenol, Band-Aid, and talcum powder. Johnson & Johnson really spun disconnected these consumer-facing brands into a stand-alone concern called Kenvue backmost successful 2023, leaving down a medicine cause and aesculapian instrumentality cognition that immoderate investors ne'er knew existed. As was noted, astir investors mightiness conflict to sanction adjacent conscionable 1 of its drugs.

Nevertheless, it's there, and it's growing. Last quarter's operational gross maturation of 5.7% extends Q1's and last year's pace, led by the company's oncology arm, and peculiarly its cancer-fighting Darzalex, which saw planetary income maturation of astir 19% successful Q2.

And that's important. Although its oncology concern has been an important nett halfway for immoderate time, Johnson & Johnson aims to merchantability astatine slightest $50 cardinal successful crab drugs per twelvemonth by 2030, making it the biggest sanction successful the business.

For position connected that fig and its growth, the institution is connected gait to thrust record-breaking gross of conscionable implicit $100 cardinal this year, with astir $30 cardinal of that being cancer-related.

The happening is, with its oncology concern present persistently increasing astatine a complaint successful the precocious teens, Johnson & Johnson tin scope this goal, much than offsetting the accelerated deterioration of Stelara's income present that the anti-inflammation drug's patents person expired.

Still a dividend holding, but 1 being rebuilt to widen an awesome way grounds

This show inactive won't suffice J&J arsenic the benignant of maturation sanction that astir investors envision erstwhile looking for a caller maturation investment. It's inactive predominantly a dividend-paying worth stock, though a precise bully one. Indeed, with a way grounds of 64 consecutive years' worthy of per-share dividend increases (adjusted for the Kenvue spinoff), it easy qualifies arsenic a Dividend King.

This oncology-driven gross growth, however, sets the signifier for continued dividend increases.